| Neuronetics, Inc. (STIM) Q1 2025 Earnings Call Transcript |
Neuronetics, Inc. (NASDAQ:STIM ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President & Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants Margaret Kaczor Andrew - William Blair William Plovanic - Canaccord Genuity Adam Maeder - Piper Sandler Danny Stauder - Citizens JMP Operator Good day, and thank you for standing by. Welcome to the Neuronetics First Quarter 2025 Financial and Operating Results Conference Call. |
seekingalpha.com |
2025-05-06 13:57:44 |
Czytaj oryginał (ang.) |
| Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates |
Neuronetics (STIM) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.27 per share a year ago. |
zacks.com |
2025-05-06 13:20:40 |
Czytaj oryginał (ang.) |
| Neuronetics Reports First Quarter 2025 Financial and Operating Results |
MALVERN, Pa., May 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2025. |
globenewswire.com |
2025-05-06 11:10:00 |
Czytaj oryginał (ang.) |
| Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
MALVERN, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 4,500 shares of the Company's common stock (RSUs) to three new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as material inducements to their respective employment with the Company. |
globenewswire.com |
2025-05-05 20:30:00 |
Czytaj oryginał (ang.) |
| Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression |
Policy update increases access for millions covered by Evernorth Health Services Policy update increases access for millions covered by Evernorth Health Services |
globenewswire.com |
2025-03-31 12:31:00 |
Czytaj oryginał (ang.) |
| Neuronetics: Explosive Growth Poised To Soar On FDA Breakthroughs |
Neuronetics has shown significant growth, with a 430% rally since November and strong Q4 2024 results, driven by its NeuroStar TMS therapy system. The company's valuation remains attractive despite recent gains, with a forward P/S ratio of 1.71x, well below sector norms, indicating potential undervaluation. Strategic acquisitions, including Greenbrook, and FDA approvals are expected to drive revenue growth and cash flow positivity by Q3 2025. |
seekingalpha.com |
2025-03-30 01:45:19 |
Czytaj oryginał (ang.) |
| Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results |
MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) is issuing this press release to update the reporting of its financial results for the fourth quarter and full year ending December 31, 2024. Following the Company's press release on March 4, 2025 initially issuing the Company's fourth quarter and full year 2024 financial results (the “Initial Release”) and in connection with finalizing the audited financial statements for the fiscal year ending December 31, 2024, certain non-cash revisions were made to the financial statements related to the Company's acquisition of Greenbrook TMS Inc. (“Greenbrook”) and the shares outstanding in the fourth quarter of 2024. These accounting updates resulted in, among other things: |
globenewswire.com |
2025-03-27 18:30:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Neuronetics (STIM) Could Surge 34.98%: Read This Before Placing a Bet |
The mean of analysts' price targets for Neuronetics (STIM) points to a 35% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-03-18 12:55:24 |
Czytaj oryginał (ang.) |
| Neuronetics, Inc. (STIM) Q4 2024 Earnings Call Transcript |
Neuronetics, Inc. (NASDAQ:STIM ) Q4 2024 Earnings Conference Call March 4, 2025 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President & Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants William Plovanic - Canaccord Genuity Max Kruszeski - William Blair Adam Maeder - Piper Sandler Danny Stauder - Citizens JMP Operator Good day, and thank you for standing by. Welcome to the Neuronetics Fourth Quarter 2024 Financial and Operating Results Conference Call. |
seekingalpha.com |
2025-03-04 11:52:10 |
Czytaj oryginał (ang.) |
| Neuronetics Reports Fourth Quarter and Full Year 2024 Financial and Operating Results |
MALVERN, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced its financial and operating results for the fourth quarter and full year of 2024. |
globenewswire.com |
2025-03-04 09:10:00 |
Czytaj oryginał (ang.) |
| Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 24,750 shares of the Company's common stock (RSUs) to three new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as material inducements to their respective employment with the Company. |
globenewswire.com |
2025-03-03 18:30:00 |
Czytaj oryginał (ang.) |
| Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 15,750 shares of the Company's common stock (RSUs) to two new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as material inducements to their respective employment with the Company. |
globenewswire.com |
2025-02-07 18:30:00 |
Czytaj oryginał (ang.) |
| Neuronetics Announces Pricing of $18 Million Underwritten Public Offering of Common Stock |
MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced that it has priced its previously announced underwritten public offering of its common stock, comprised of 8,000,000 shares of common stock at a public offering price of $2.25 per share, resulting in gross proceeds of approximately $18 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. |
globenewswire.com |
2025-02-07 09:54:00 |
Czytaj oryginał (ang.) |
| Neuronetics Announces Launch of Underwritten Public Offering of Common Stock |
MALVERN, Pa., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced that it has commenced an underwritten public offering of its common stock. In connection with the offering, the Company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All shares in the offering are being offered by the Company. |
globenewswire.com |
2025-02-06 18:23:00 |
Czytaj oryginał (ang.) |
| NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression |
Advancing mental health treatment through innovative research, offering insights on symptom improvement and clinical tools Advancing mental health treatment through innovative research, offering insights on symptom improvement and clinical tools |
globenewswire.com |
2025-01-29 10:31:00 |
Czytaj oryginał (ang.) |
| Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
MALVERN, Pa., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the granting of inducement awards to a new employee as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by the Compensation Committee of the Company's Board of Directors and were made as material inducements to the recipients' employment with the Company. In all cases, vesting is subject to the recipient's continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company's 2020 Inducement Incentive Plan. |
globenewswire.com |
2024-12-18 18:30:00 |
Czytaj oryginał (ang.) |
| Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
MALVERN, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”) today announced the granting of inducement awards to new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by the Compensation Committee of the Company's Board of Directors and were made as material inducements to the recipients' employment with the Company. In all cases, vesting is subject to the recipient's continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company's 2020 Inducement Incentive Plan. |
globenewswire.com |
2024-12-16 18:30:00 |
Czytaj oryginał (ang.) |
| Neuronetics and Greenbrook TMS Announce Closing of Transaction |
MALVERN, Pa. and TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (“Neuronetics”) and Greenbrook TMS Inc. (OTCMKTS: GBNHF) (“Greenbrook”, and together with Neuronetics, the “Combined Company”) today announced that they have successfully completed the previously announced transaction whereby Neuronetics acquired all of the issued and outstanding common shares of Greenbrook (the “Greenbrook Shares”) by way of a court-approved plan of arrangement under the Business Corporations Act (Ontario) (the “Arrangement”). Each Greenbrook Share outstanding immediately prior to the effective time of the Arrangement was exchanged for 0.01021 of a share of common stock of Neuronetics (the “Exchange Ratio”) upon closing of the Arrangement. |
globenewswire.com |
2024-12-10 12:00:00 |
Czytaj oryginał (ang.) |
| Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference |
MALVERN, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024. The Company is scheduled to present at 2:30pm Eastern Time the same day via webcast. |
globenewswire.com |
2024-11-20 10:30:00 |
Czytaj oryginał (ang.) |
| Neuronetics, Inc. (STIM) Q3 2024 Earnings Call Transcript |
Neuronetics, Inc. (NASDAQ:STIM ) Q3 2024 Earnings Call November 12, 2024 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President and Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants William Plovanic - Canaccord Genuity James Beers - William Blair Danny Stauder - JMP Operator Good day and thank you for standing by. Welcome to the Neuronetics Third Quarter 2024 Financial and Operating Results Conference Call. |
seekingalpha.com |
2024-11-12 22:41:48 |
Czytaj oryginał (ang.) |
| CORRECTION—Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results |
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- In a release issued earlier today under the same headline by Neuronetics, Inc. (NASDAQ: STIM), please note that in the second paragraph of the "Stockholders Approve Acquisition of Greenbrook TMS" section, it should say that the Company expects to achieve cash flow breakeven by the third quarter of 2025, not the second. The corrected release follows: |
globenewswire.com |
2024-11-12 20:45:00 |
Czytaj oryginał (ang.) |
| Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 13,500 shares of the Company's common stock (RSUs) to seven new non-executive employees. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as material inducements to their respective employment with the Company. |
globenewswire.com |
2024-11-12 18:30:00 |
Czytaj oryginał (ang.) |
| Neuronetics (STIM) Reports Q3 Loss, Lags Revenue Estimates |
Neuronetics (STIM) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.33 per share a year ago. |
zacks.com |
2024-11-12 11:21:10 |
Czytaj oryginał (ang.) |
| Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results |
MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the third quarter of 2024. |
globenewswire.com |
2024-11-12 09:10:00 |
Czytaj oryginał (ang.) |
| Neuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call |
MALVERN, Pa., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release third quarter 2024 financial and operating results prior to market open on Tuesday, November 12, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. |
globenewswire.com |
2024-10-29 18:30:00 |
Czytaj oryginał (ang.) |
| NeuroStar® Oral Presentation at AACAP 2024 Highlights Largest Study Evaluating TMS Efficacy in Adolescents with Depression |
Data selected for oral presentation reinforce previous findings on safety and efficacy Data selected for oral presentation reinforce previous findings on safety and efficacy |
globenewswire.com |
2024-10-14 12:31:00 |
Czytaj oryginał (ang.) |
| Neuronetics and Greenbrook TMS Announce Receipt of Interim Order in Respect of Proposed Arrangement and Provide Details of Shareholder Meetings |
MALVERN, Pa. and TORONTO , Oct. 4, 2024 /PRNewswire/ - Neuronetics, Inc. (NASDAQ: STIM) ("Neuronetics") and Greenbrook TMS Inc. (OTCMKTS: GBNHF) ("Greenbrook") today announced that the Ontario Superior Court of Justice (Commercial List) (the "Court") has granted an interim order (the "Interim Order") in connection with the previously announced statutory plan of arrangement under section 182 of the Business Corporations Act (Ontario) (the "Plan of Arrangement"), pursuant to which, subject to the satisfaction or waiver of all applicable conditions precedent, Neuronetics will acquire all of the issued and outstanding common shares of Greenbrook ("Greenbrook Shares") in an all-stock transaction (the "Arrangement"). |
prnewswire.com |
2024-10-04 12:33:00 |
Czytaj oryginał (ang.) |
| Health Care Service Corporation Adds First-Line TMS Coverage for Adolescents |
Policy update increases access for millions covered by HCSC BlueCross BlueShield policies Policy update increases access for millions covered by HCSC BlueCross BlueShield policies |
globenewswire.com |
2024-09-25 12:31:00 |
Czytaj oryginał (ang.) |
| STIM Stock Likely to Gain From Updated TMS Coverage |
Neuronetics announces that TMS coverage has been updated to reduce access barriers for patients with MDD. In line with this, BCBS and Louisiana Medicaid have expanded their TMS coverage. |
zacks.com |
2024-09-23 18:31:07 |
Czytaj oryginał (ang.) |
| Expanded Health Policies Enhance TMS Therapy Access for Adolescents and Adults |
BlueCross BlueShield of North Carolina and Louisiana Medicaid Increase Coverage for Patients with Depression BlueCross BlueShield of North Carolina and Louisiana Medicaid Increase Coverage for Patients with Depression |
globenewswire.com |
2024-09-19 12:31:00 |
Czytaj oryginał (ang.) |
| NeuroStar® Releases Software Upgrades to Elevate Patient Care |
Upgrades improve communication, streamline data management, and strengthen security Upgrades improve communication, streamline data management, and strengthen security |
globenewswire.com |
2024-09-16 12:32:00 |
Czytaj oryginał (ang.) |
| NeuroStar Honors Suicide Prevention Month With Milestone Achievement and Powerful Stories |
NeuroStar Is More Than Halfway to Achieving Its Five-Year Goal of Saving Thousands of Lives NeuroStar Is More Than Halfway to Achieving Its Five-Year Goal of Saving Thousands of Lives |
globenewswire.com |
2024-09-03 12:29:00 |
Czytaj oryginał (ang.) |
| Neuronetics' (STIM) Latest Deal to Aid Mental Health Treatments |
Neuronetics (STIM) announces the acquisition of Greenbrook to provide better care to patients suffering from mental health conditions. |
zacks.com |
2024-08-13 18:01:09 |
Czytaj oryginał (ang.) |
| Neuronetics (STIM) Inks a New Merger Agreement With Greenbrook |
Neuronetics (STIM) signs a merger agreement with Greenbrook to acquire all its outstanding shares. The transaction is expected to be closed during the fourth quarter of 2024. |
zacks.com |
2024-08-13 17:50:34 |
Czytaj oryginał (ang.) |
| Neuronetics (STIM) Q2 Loss Wider Than Expected, Revenues Fall Y/Y |
Neuronetics' (STIM) second-quarter 2024 top-line results reflect lower revenues from NeuroStar Advanced Therapy System and Treatment sessions. |
zacks.com |
2024-08-13 14:45:58 |
Czytaj oryginał (ang.) |